Drugs / Enfortumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enfortumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06204614 ↗ |
| Known as | AGS-22C3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301579 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3301579 ↗ |